Cidara Therapeutics' Presentations At ASH 2016 To Highlight Potential Role Of Novel Antifungal CD101 In Patients With Hematologic Malignancies

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego from December 3-6, 2016. CD101 is Cidara's lead antifungal drug candidate and the only long-acting antifungal in the echinocandin class.

"Patients with blood cancers and those undergoing transplantation are at much higher risk for opportunistic fungal infections, often the cause of significant morbidity and mortality," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "We are pleased to be sharing data at this year's ASH meeting that demonstrate the potential of our novel compound CD101 to treat and prevent deadly fungal infections in blood cancer patients."

CD101 data accepted for presentation at this year's ASH Annual Meeting comprise the following:
  • Two poster presentations evaluating the efficacy of CD101 for the treatment and prevention of invasive fungal infections due to the pathogens, Candida, Aspergillus and Pneumocystis.
  • A poster presentation summarizing results from the successful Phase 1 clinical trial of CD101 IV, demonstrating the safety and pharmacokinetics of single and multiple weekly dosing regimens.

Approximately 97,000 Americans die from hospital-related fungal infections each year and 90 percent of these infections are caused by two common fungi, Candida and Aspergillus. Systemic fungal infections typically affect patients whose immune systems have been compromised, such as patients undergoing organ or bone marrow transplantation or chemotherapy including patients with hematologic malignancies. Pneumocystis is another serious fungal infection that commonly afflicts people with weakened immune systems.

"Invasive fungal infections remain a significant threat in patients with hematological cancer and in transplant recipients. Although significant progress has been made in diagnostics and the introduction of new agents, significant challenges remain," said Dimitrios P. Kontoyiannis, M.D., of The University of Texas MD Anderson Cancer Center. "Current antifungals have several issues with suboptimal pharmacokinetics, frequent drug-to-drug interactions and contraindications with chemotherapy or immunosuppressants, toxicity and suboptimal efficacy, especially as fungal resistance is on the rise. There is an unmet need for new antifungal therapies that are safe and effective with low toxicity."

If you liked this article you might like

IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up